Through 90-minute group sessions, participants explore the practical how and why of lifestyle medicine, learning how nutrition, movement, sleep, and stress management can influence metabolic health
Key takeaways: across all five SURMOUNT trials, Zepbound consistently produced 14% to 22.5% average weight loss, with the head-to-head data confirming superior efficacy compared to the leading semaglutide-based alternative
Bcl-2 is a novel interacting partner for the 2-oxoglutarate carrier and a key regulator of mitochondrial glutathione
The hospital stay after the procedure is a few hours
The calculation process remains identical
However, discontinuation rates are similar for both treatments (approximately 6%), suggesting that while CagriSema causes more frequent gastrointestinal symptoms, they are generally manageable